The mechanism of action of the factor in leprosy serum that inhibits the growth of mitogen-stimulated normal human lymphocytes
- PMID: 3496268
- PMCID: PMC1453379
The mechanism of action of the factor in leprosy serum that inhibits the growth of mitogen-stimulated normal human lymphocytes
Abstract
A factor found in the serum of patients with leprosy that inhibits the growth of mitogen-stimulated normal peripheral blood lymphocytes has been studied. The inhibitor, previously identified as an IgG, has been shown to act by blocking the recruitment of lymphocytes into growth. It was not cytotoxic and did not inhibit the rate of growth of those lymphocytes that had been stimulated. The inhibitory activity was less potent if the serum was added after mitogen stimulation. The inhibitor, which could be absorbed by activated but not resting lymphocyte cultures, appeared to act by inhibition of an early event preceding the release of IL-2. The inhibition of mitogen stimulation was overcome by the addition of purified IL-2, although the inhibitor did not block the action of IL-2 on a long-term cultured IL-2-dependent cell line.
Similar articles
-
Characterization of a factor in leprosy serum that inhibits the growth of mitogen-stimulated normal human lymphocytes.Immunology. 1987 Jun;61(2):117-23. Immunology. 1987. PMID: 3596636 Free PMC article.
-
Suppress of the increase in free cytosolic calcium during the inhibition of T-cell activation by an autoantibody present in the serum of leprosy patients.Immunology. 1989 Nov;68(3):353-8. Immunology. 1989. PMID: 2592010 Free PMC article.
-
Effect of phorbol myristate acetate (PMA) and ionophore A23187 on interleukin-2 levels and proliferation of activated T lymphocytes from patients with lepromatous leprosy.Int J Lepr Other Mycobact Dis. 1997 Mar;65(1):73-9. Int J Lepr Other Mycobact Dis. 1997. PMID: 9207756
-
Serum inhibitors of interleukin-2.Life Sci. 1988;42(16):1485-91. doi: 10.1016/0024-3205(88)90004-5. Life Sci. 1988. PMID: 3280939 Review.
-
Human nonspecific suppressive lymphokines.J Clin Immunol. 1991 Jan;11(1):1-12. doi: 10.1007/BF00918789. J Clin Immunol. 1991. PMID: 2022719 Review.
Cited by
-
Tuberculous anergic sera or purified protein derivative treatment induces modification in lymphocyte transformation of cells from patients with tuberculosis.J Clin Microbiol. 1990 Feb;28(2):344-9. doi: 10.1128/jcm.28.2.344-349.1990. J Clin Microbiol. 1990. PMID: 2312677 Free PMC article.
-
Changes in activation markers and cell membrane receptors on human peripheral blood T lymphocytes during cell cycle progression after PHA stimulation.Immunology. 1988 Jul;64(3):419-25. Immunology. 1988. PMID: 3261709 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical